Kepler-102 : masses and compositions for a super-Earth and sub-Neptune orbiting an active star

Funding: This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under grant No. 1842402. C.L.B., L.W., and D.H. acknowledge support from National Aeronautics and Space Administration (grant No. 80NSSC19K0597) issued through the Astrophysics Data Analysis Program. D.H. also acknowledges support from the Alfred P. Sloan Foundation. K.R. acknowledges support from the UK STFC via grant No. ST/V000594/1. E.G. acknowledges support from NASA grant No. 80NSSC20K0957 (Exoplanets Research Program).Radial velocity (RV) measurements of transiting multiplanet systems allow us to understand the densities and compositions of planets unlike those in the solar system. Kepler-102, which consists of five tightly packed transiting planets, is a particularly interesting system since it includes a super-Earth (Kepler-102d) and a sub-Neptune-sized planet (Kepler-102e) for which masses can be measured using RVs. Previous work found a high density for Kepler-102d, suggesting a composition similar to that of Mercury, while Kepler-102e was found to have a density typical of sub-Neptune size planets; however, Kepler-102 is an active star, which can interfere with RV mass measurements. To better measure the mass of these two planets, we obtained 111 new RVs using Keck/HIRES and Telescopio Nazionale Galileo/HARPS-N and modeled Kepler-102's activity using quasiperiodic Gaussian process regression. For Kepler-102d, we report a mass upper limit Md < 5.3 M⊕ (95% confidence), a best-fit mass Md = 2.5 ± 1.4 M⊕, and a density ρd = 5.6 ± 3.2 g cm−3, which is consistent with a rocky composition similar in density to the Earth. For Kepler-102e we report a mass Me = 4.7 ± 1.7 M⊕ and a density ρe = 1.8 ± 0.7 g cm−3. These measurements suggest that Kepler-102e has a rocky core with a thick gaseous envelope comprising 2%–4% of the planet mass and 16%–50% of its radius. Our study is yet another demonstration that accounting for stellar activity in stars with clear rotation signals can yield more accurate planet masses, enabling a more realistic interpretation of planet interiors.Publisher PDFPeer reviewe

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

Background: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting. Methodology: We developed and implemented an optimized mutation profiling platform (“OncoMap”) to interrogate ∼400 mutations in 33 known oncogenes and tumor suppressors, many of which are known to predict response or resistance to targeted therapies. The performance of OncoMap was analyzed using DNA derived from both frozen and FFPE clinical material in a diverse set of cancer types. A subsequent in-depth analysis was conducted on histologically and clinically annotated pediatric gliomas. The sensitivity and specificity of OncoMap were 93.8% and 100% in fresh frozen tissue; and 89.3% and 99.4% in FFPE-derived DNA. We detected known mutations at the expected frequencies in common cancers, as well as novel mutations in adult and pediatric cancers that are likely to predict heightened response or resistance to existing or developmental cancer therapies. OncoMap profiles also support a new molecular stratification of pediatric low-grade gliomas based on BRAF mutations that may have immediate clinical impact. Conclusions: Our results demonstrate the clinical feasibility of high-throughput mutation profiling to query a large panel of “actionable” cancer gene mutations. In the future, this type of approach may be incorporated into both cancer epidemiologic studies and clinical decision making to specify the use of many targeted anticancer agents

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

BACKGROUND: Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the implementation of a genotyping and validation algorithm that enables robust tumor mutation profiling in the clinical setting. METHODOLOGY: We developed and implemented an optimized mutation profiling platform ("OncoMap") to interrogate approximately 400 mutations in 33 known oncogenes and tumor suppressors, many of which are known to predict response or resistance to targeted therapies. The performance of OncoMap was analyzed using DNA derived from both frozen and FFPE clinical material in a diverse set of cancer types. A subsequent in-depth analysis was conducted on histologically and clinically annotated pediatric gliomas. The sensitivity and specificity of OncoMap were 93.8% and 100% in fresh frozen tissue; and 89.3% and 99.4% in FFPE-derived DNA. We detected known mutations at the expected frequencies in common cancers, as well as novel mutations in adult and pediatric cancers that are likely to predict heightened response or resistance to existing or developmental cancer therapies. OncoMap profiles also support a new molecular stratification of pediatric low-grade gliomas based on BRAF mutations that may have immediate clinical impact. CONCLUSIONS: Our results demonstrate the clinical feasibility of high-throughput mutation profiling to query a large panel of "actionable" cancer gene mutations. In the future, this type of approach may be incorporated into both cancer epidemiologic studies and clinical decision making to specify the use of many targeted anticancer agents

Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease

STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti-IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder

Global urban environmental change drives adaptation in white clover

Urbanization transforms environments in ways that alter biological evolution. We examined whether urban environmental change drives parallel evolution by sampling 110,019 white clover plants from 6169 populations in 160 cities globally. Plants were assayed for a Mendelian antiherbivore defense that also affects tolerance to abiotic stressors. Urban-rural gradients were associated with the evolution of clines in defense in 47% of cities throughout the world. Variation in the strength of clines was explained by environmental changes in drought stress and vegetation cover that varied among cities. Sequencing 2074 genomes from 26 cities revealed that the evolution of urban-rural clines was best explained by adaptive evolution, but the degree of parallel adaptation varied among cities. Our results demonstrate that urbanization leads to adaptation at a global scale